NeoGenomics Completes Acquisition of Pathline
NeoGenomics (NASDAQ:NEO) has successfully completed its acquisition of Pathline, , a CLIA/CAP/NYS-certified laboratory located in New Jersey. The strategic acquisition strengthens NeoGenomics' commercial footprint in the Northeast United States, particularly in the Tri-state area.
The merger aims to expand access to NeoGenomics' comprehensive oncology test menu and enhance service capabilities, with a focus on accelerating growth in molecular and hematology-oncology testing. This development will provide patients and physicians in the region with broader access to NeoGenomics' high-quality laboratory services.
NeoGenomics (NASDAQ:NEO) ha completato con successo l'acquisizione di Pathline, un laboratorio certificato CLIA/CAP/NYS situato nel New Jersey. Questa acquisizione strategica rafforza la presenza commerciale di NeoGenomics nel Nord-est degli Stati Uniti, in particolare nell'area dei Tri-state.
La fusione ha l'obiettivo di ampliare l'accesso al menu completo di test oncologici di NeoGenomics e migliorare le capacità di servizio, con un focus sull'accelerazione della crescita nei test di oncologia molecolare e ematologica. Questo sviluppo offrirà ai pazienti e ai medici della regione un accesso più ampio ai servizi di laboratorio di alta qualità di NeoGenomics.
NeoGenomics (NASDAQ:NEO) ha completado con éxito la adquisición de Pathline, un laboratorio certificado por CLIA/CAP/NYS ubicado en Nueva Jersey. Esta adquisición estratégica fortalece la huella comercial de NeoGenomics en el noreste de Estados Unidos, especialmente en el área de los Tri-state.
La fusión tiene como objetivo expandir el acceso al completo menú de pruebas oncológicas de NeoGenomics y mejorar las capacidades de servicio, con un enfoque en acelerar el crecimiento en pruebas de oncología molecular y hematológica. Este desarrollo proporcionará a pacientes y médicos en la región un acceso más amplio a los servicios de laboratorio de alta calidad de NeoGenomics.
NeoGenomics (NASDAQ:NEO)는 뉴저지에 위치한 CLIA/CAP/NYS 인증 실험실인 Pathline의 인수를 성공적으로 완료했습니다. 이 전략적 인수는 북동부 미국, 특히 삼주 지역에서 NeoGenomics의 상업적 입지를 강화합니다.
이번 합병은 NeoGenomics의 포괄적인 종양학 테스트 메뉴에 대한 접근을 확대하고 서비스 능력을 향상시키는 것을 목표로 하며, 분자 및 혈액 종양학 테스트에서의 성장을 가속화하는 데 중점을 두고 있습니다. 이 발전은 지역의 환자와 의사에게 NeoGenomics의 고품질 실험실 서비스에 대한 더 넓은 접근을 제공할 것입니다.
NeoGenomics (NASDAQ:NEO) a réussi à finaliser l'acquisition de Pathline, un laboratoire certifié CLIA/CAP/NYS situé dans le New Jersey. Cette acquisition stratégique renforce l'empreinte commerciale de NeoGenomics dans le nord-est des États-Unis, en particulier dans la région des Tri-state.
La fusion vise à élargir l'accès au menu complet des tests oncologiques de NeoGenomics et à améliorer les capacités de service, en mettant l'accent sur l'accélération de la croissance dans les tests d'oncologie moléculaire et hématologique. Ce développement offrira aux patients et aux médecins de la région un accès plus large aux services de laboratoire de haute qualité de NeoGenomics.
NeoGenomics (NASDAQ:NEO) hat erfolgreich die Übernahme von Pathline, einem CLIA/CAP/NYS-zertifizierten Labor in New Jersey, abgeschlossen. Diese strategische Übernahme stärkt die kommerzielle Präsenz von NeoGenomics im Nordosten der Vereinigten Staaten, insbesondere im Tri-State-Gebiet.
Die Fusion zielt darauf ab, den Zugang zum umfassenden Onkologie-Testangebot von NeoGenomics zu erweitern und die Servicefähigkeiten zu verbessern, mit einem Schwerpunkt auf der Beschleunigung des Wachstums in der molekularen und hämatologischen Onkologie-Testung. Diese Entwicklung wird Patienten und Ärzten in der Region einen breiteren Zugang zu den hochwertigen Laborleistungen von NeoGenomics bieten.
- Strategic expansion into Northeast U.S. market
- Enhanced service capabilities in molecular and hematology-oncology testing
- Access to Pathline's CLIA/CAP/NYS certifications
- Broader market reach in the Tri-state area
- None.
Patients and physicians will benefit from access to NeoGenomics’ broad test menu and high-quality laboratory services in the Tri-state area
With the acquisition, NeoGenomics strengthens its commercial presence in the
About NeoGenomics, Inc.
NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250407427587/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Andrea Sampson
asampson@sampsonprgroup.com
Source: NeoGenomics, Inc.
FAQ
What is the strategic importance of NeoGenomics' Pathline acquisition?
How will the Pathline acquisition affect NeoGenomics' (NEO) service offerings?
What certifications does the acquired Pathline laboratory hold?
Which geographical regions will benefit from NeoGenomics' Pathline acquisition?
